Arovella Appoints CEO
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Dr. Van Der Weerden, who previously served as Chief Operating Officer, brings extensive experience from her time at Hexima Ltd. The Chairman expressed confidence in her leadership and the company's recent achievements in clinical development. Dr. Van Der Weerden's compensation package includes a base salary and potential bonuses based on performance.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Arovella Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Arovella Therapeutics
- First Patient Dosed with ALA-101
- Quarterly Activities/Appendix 4C Cash Flow Report
- Arovella receives R&D tax rebate of $4.03 million
- Second Clinical Batch Released for Immediate Patient Use
- The path to first patient dosing
Later from Arovella Therapeutics
All Arovella Therapeutics news releasesFollow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics